SMAD2 and pulmonary fibrosis: Inhibiting TRIM47 expression can suppress the expression of Vimentin, α-SMA, and CTGF protein, reduce Smad2/3 phosphorylation and hydroxyproline production, thereby mitigating pulmonary fibrosis.